Page last updated: 2024-08-18

pyrazolanthrone and Leukemia, Myelomonocytic, Juvenile

pyrazolanthrone has been researched along with Leukemia, Myelomonocytic, Juvenile in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chan, EM; Chan, RJ; Flotho, C; Hashino, E; Kondo, T; Kratz, CP; Nabinger, SC; Ndong, L; Niemeyer, CM; Voorhorst, CS; Würstlin, O; Yang, Z; Yin, F; Yu, M1

Other Studies

1 other study(ies) available for pyrazolanthrone and Leukemia, Myelomonocytic, Juvenile

ArticleYear
Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.
    Molecular and cellular biology, 2009, Volume: 29, Issue:16

    Topics: Animals; Anthracenes; Cell Differentiation; Child; Enzyme Activation; GATA2 Transcription Factor; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; Infant; JNK Mitogen-Activated Protein Kinases; Leukemia, Myelomonocytic, Juvenile; Mast Cells; Mice; Monocytes; Mutation; NIH 3T3 Cells; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 11; ras Proteins; Receptor, Macrophage Colony-Stimulating Factor

2009